chloroquine has been researched along with Insulin Sensitivity in 9 studies
Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.
chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the mechanism of chloroquine improving insulin sensitivity." | 7.70 | [Effects of chloroquine on insulin sensitivity in insulin-resistant rats]. ( Li, C; Shu, C; Zhang, S, 1999) |
| "To investigate the mechanism of chloroquine improving insulin sensitivity." | 3.70 | [Effects of chloroquine on insulin sensitivity in insulin-resistant rats]. ( Li, C; Shu, C; Zhang, S, 1999) |
| "Chloroquine and 3-MA were employed." | 1.72 | Psoralen Suppresses Lipid Deposition by Alleviating Insulin Resistance and Promoting Autophagy in Oleate-Induced L02 Cells. ( Huang, W; Li, F; Li, X; Ma, Y; Sun, X; Wang, Y; Xu, M; Yu, D; Zhang, Y; Zou, J, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (33.33) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 2 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, Y | 2 |
| Li, F | 1 |
| Zou, J | 1 |
| Li, X | 1 |
| Xu, M | 1 |
| Yu, D | 1 |
| Ma, Y | 1 |
| Huang, W | 1 |
| Sun, X | 1 |
| Zhang, Y | 1 |
| Chee, YJ | 1 |
| Tan, SK | 1 |
| Yeoh, E | 1 |
| Lee, LS | 1 |
| Leow, MK | 1 |
| Xu, Y | 1 |
| Wilder-Smith, A | 1 |
| Cheung, YB | 1 |
| Paton, NI | 1 |
| Razani, B | 1 |
| Feng, C | 1 |
| Semenkovich, CF | 1 |
| Ahmed, MH | 1 |
| Blazar, BR | 1 |
| Whitley, CB | 1 |
| Kitabchi, AE | 1 |
| Tsai, MY | 1 |
| Santiago, J | 1 |
| White, N | 1 |
| Stentz, FB | 1 |
| Brown, DM | 1 |
| Walker, AP | 1 |
| Flint, DJ | 1 |
| Li, C | 1 |
| Zhang, S | 1 |
| Shu, C | 1 |
| Prince, MJ | 1 |
| Smith, FE | 1 |
| Peters, EJ | 1 |
| Stuart, CA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Metabolic Effects of Hydroxychloroquine[NCT02026232] | 21 participants (Actual) | Interventional | 2012-03-31 | Terminated (stopped due to COVID-19 & loss of funding) | |||
| Genotoxic Stress, Atherosclerosis, and Metabolic Syndrome-AIM 2[NCT00455325] | Phase 2 | 35 participants (Actual) | Interventional | 2004-09-30 | Completed | ||
| Genotoxic Stress, Atherosclerosis, and Metabolic Syndrome- Aim 3[NCT00455403] | 357 participants (Actual) | Interventional | 2006-04-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
determined by fasting blood glucose performed at baseline and follow-up (NCT02026232)
Timeframe: 4 weeks
| Intervention | mg/dL (Mean) | |
|---|---|---|
| Baseline Glucose (mg/dL) | Follow-up Glucose (mg/dL) | |
| Hydroxychloroquine | 186.9 | 165.9 |
| Placebo | 163.1 | 158.8 |
determined by lipid profile with calculated LDL performed at baseline and follow-up (NCT02026232)
Timeframe: 4 weeks
| Intervention | mg/dL (Mean) | |
|---|---|---|
| Baseline - LDL (mg/dL) | Follow-up - LDL (mg/dL) | |
| Hydroxychloroquine | 90.4 | 72.4 |
| Placebo | 92.8 | 87.7 |
Two techniques were employed: auscultation of seated subjects at rest was performed by a trained observer who recorded the first and fifth phases of the Korotkoff sounds; and, a portable oscillometric device (SpaceLabs Medical) recorded results every 20 min during the day and every hour during the night. Data were analyzed as mean values over 24 hours. (NCT00455325)
Timeframe: Assessed every 8-10 weeks at the end of each treatment period.
| Intervention | mmHg (Mean) |
|---|---|
| Placebo Comparator: First Intervention (3 Weeks) | 70 |
| Second Intervention (3 Weeks) | 71 |
| Third Intervention (3 Weeks) | 73 |
| Fourth Intervention (3 Weeks) | 73 |
Hepatic insulin sensitivity was measured by comparing glucose production at baseline of zero insulin infusion rate with glucose production at 56 pmol/m2/min. Hepatic insulin sensitivity was expressed as the percent suppression, such that greater percent suppression indicated greater hepatic insulin sensitivity. There are no reference values, since the patients served as their own controls. (NCT00455325)
Timeframe: assessed every 8 - 10 weeks at the end of each treatment period
| Intervention | % suppression inf rate 56 pmol/m2/min (Mean) |
|---|---|
| Placebo Comparator: First Intervention (3 Weeks) | .56 |
| Second Intervention (3 Weeks) | 0.55 |
| Third Intervention (3 Weeks) | 0.66 |
| Fourth Intervention (3 Weeks) | 0.70 |
Fasting Serum Blood Sample (NCT00455325)
Timeframe: Assessed every 8-10 weeks at the end of each treatment period.
| Intervention | mg/dl (Mean) |
|---|---|
| Placebo Comparator: First Intervention (3 Weeks) | 115 |
| Second Intervention (3 Weeks) | 109 |
| Third Intervention (3 Weeks) | 109 |
| Fourth Intervention (3 Weeks) | 103 |
Fasting Serum Blood Sample (NCT00455325)
Timeframe: Assessed every 8-10 weeks at the end of each treatment period.
| Intervention | mg/dL (Mean) |
|---|---|
| Placebo Comparator: First Intervention (3 Weeks) | 144 |
| Second Intervention (3 Weeks) | 139 |
| Third Intervention (3 Weeks) | 139 |
| Fourth Intervention (3 Weeks) | 131 |
Two techniques were employed: auscultation of seated subjects at rest was performed by a trained observer who recorded the first and fifth phases of the Korotkoff sounds; and, a portable oscillometric device (SpaceLabs Medical) recorded results every 20 min during the day and every hour during the night. Data were analyzed as mean values over 24 hours. (NCT00455325)
Timeframe: Assessed every 8-10 weeks at the end of each treatment period
| Intervention | mmHg (Mean) |
|---|---|
| Placebo Comparator: First Intervention (3 Weeks) | 121 |
| Second Intervention (3 Weeks) | 121 |
| Third Intervention (3 Weeks) | 123 |
| Fourth Intervention (3 Weeks) | 123 |
Fasting Serum Blood Sample (NCT00455325)
Timeframe: Assessed every 8-10 weeks at the end of each treatment period.
| Intervention | mg/dL (Mean) |
|---|---|
| Placebo Comparator: First Intervention (3 Weeks) | 187 |
| Second Intervention (3 Weeks) | 181 |
| Third Intervention (3 Weeks) | 182 |
| Fourth Intervention (3 Weeks) | 173 |
Fasting Serum Blood Sample (NCT00455325)
Timeframe: Assessed every 8-10 weeks at the end of each treatment period.
| Intervention | mg/dL (Mean) |
|---|---|
| Placebo Comparator: First Intervention (3 Weeks) | 143 |
| Second Intervention (3 Weeks) | 153 |
| Third Intervention (3 Weeks) | 151 |
| Fourth Intervention (3 Weeks) | 140 |
A noninvasive predictor of cardiovascular events, Carotid artery intima-media thickness (CIMT) was measured from B-mode images by a single sonographer using standard approaches (NCT00455403)
Timeframe: Measured at baseline and year 1
| Intervention | millmeter (Mean) | |
|---|---|---|
| Baseline | Year 1 | |
| Chloroquine Subjects | 0.766 | 0.758 |
| Placebo Subjects | 0.765 | 0.768 |
1 review available for chloroquine and Insulin Sensitivity
| Article | Year |
|---|---|
Dissecting the interaction between COVID-19 and diabetes mellitus.
Topics: Antibodies, Monoclonal, Humanized; Antiviral Agents; Blood Glucose; Chloroquine; Comorbidity; COVID- | 2020 |
1 trial available for chloroquine and Insulin Sensitivity
| Article | Year |
|---|---|
Low-dose chloroquine is associated with favourable effects on lipoprotein metabolism without significant influence on insulin resistance.
Topics: Adult; Blood Glucose; Chloroquine; Cholesterol; Dose-Response Relationship, Drug; Drug Administratio | 2016 |
7 other studies available for chloroquine and Insulin Sensitivity
| Article | Year |
|---|---|
Psoralen Suppresses Lipid Deposition by Alleviating Insulin Resistance and Promoting Autophagy in Oleate-Induced L02 Cells.
Topics: AMP-Activated Protein Kinases; Autophagy; Chloroquine; Ficusin; Humans; Insulin Resistance; Lipid Me | 2022 |
p53 is required for chloroquine-induced atheroprotection but not insulin sensitization.
Topics: Animals; Antimalarials; Ataxia Telangiectasia Mutated Proteins; Atherosclerosis; Blood Glucose; Cell | 2010 |
p53 is required for chloroquine-induced atheroprotection but not insulin sensitization.
Topics: Animals; Antimalarials; Ataxia Telangiectasia Mutated Proteins; Atherosclerosis; Blood Glucose; Cell | 2010 |
p53 is required for chloroquine-induced atheroprotection but not insulin sensitization.
Topics: Animals; Antimalarials; Ataxia Telangiectasia Mutated Proteins; Atherosclerosis; Blood Glucose; Cell | 2010 |
p53 is required for chloroquine-induced atheroprotection but not insulin sensitization.
Topics: Animals; Antimalarials; Ataxia Telangiectasia Mutated Proteins; Atherosclerosis; Blood Glucose; Cell | 2010 |
p53 is required for chloroquine-induced atheroprotection but not insulin sensitization.
Topics: Animals; Antimalarials; Ataxia Telangiectasia Mutated Proteins; Atherosclerosis; Blood Glucose; Cell | 2010 |
p53 is required for chloroquine-induced atheroprotection but not insulin sensitization.
Topics: Animals; Antimalarials; Ataxia Telangiectasia Mutated Proteins; Atherosclerosis; Blood Glucose; Cell | 2010 |
p53 is required for chloroquine-induced atheroprotection but not insulin sensitization.
Topics: Animals; Antimalarials; Ataxia Telangiectasia Mutated Proteins; Atherosclerosis; Blood Glucose; Cell | 2010 |
p53 is required for chloroquine-induced atheroprotection but not insulin sensitization.
Topics: Animals; Antimalarials; Ataxia Telangiectasia Mutated Proteins; Atherosclerosis; Blood Glucose; Cell | 2010 |
p53 is required for chloroquine-induced atheroprotection but not insulin sensitization.
Topics: Animals; Antimalarials; Ataxia Telangiectasia Mutated Proteins; Atherosclerosis; Blood Glucose; Cell | 2010 |
Chloroquine-induced nitric oxide improves insulin sensitivity in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Chloroquine; Glucose; Humans; Insulin Resistance; Nitric Oxide | 2006 |
In vivo chloroquine-induced inhibition of insulin degradation in a diabetic patient with severe insulin resistance.
Topics: Adipose Tissue; Adult; alpha-Galactosidase; beta-N-Acetylhexosaminidases; Biopsy; Chloroquine; Diabe | 1984 |
Absence of down-regulation of the insulin receptor by insulin. A possible mechanism of insulin resistance in the rat.
Topics: Adipose Tissue; Animals; Bacitracin; Cells, Cultured; Chloroquine; Female; Insulin; Insulin Resistan | 1983 |
[Effects of chloroquine on insulin sensitivity in insulin-resistant rats].
Topics: Animals; Chloroquine; Deoxyglucose; Glucose Clamp Technique; Insulin; Insulin Resistance; Liver; Mal | 1999 |
Functional characteristics of decreased insulin receptors on fibroblasts obtained from a subject with severe insulin resistance and acanthosis nigricans.
Topics: Acanthosis Nigricans; Adolescent; Cells, Cultured; Chloroquine; Deoxyglucose; Dose-Response Relation | 1986 |